In recent trading, Lightwave Logic Inc (LWLG) stock price has shown some volatility, fluctuating 8.55% over the last five trades and 11.88% over the past 30 trades. This represents a notable shift ...

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's ...

Demonstration Combines Polariton's High-Speed Plasmonic Modulators with Lightwave's Perkinamine™ Chromophores in a Packaged Device ENGLEWOOD, Colo. and ADLISWIL, Switzerland, Sept. 24 ...

Lightwave Logic, Inc. (NASDAQ: LWLG), a technology platform company leveraging its proprietary electro-optic (EO) polymers to ...

On Monday, Lightwave Logic Inc (LWLG) stock saw a decline, ending the day at $2.76 which represents a decrease of $-0.19 or -6.44% from the prior close of $2.95. The stock opened at $2.95 and touched ...

Imagine a future where indoor wireless communication systems handle skyrocketing data demands and do so with unmatched ...

The phase II LIGHTWAVE study evaluating Sage Therapeutics' dalzanemdor for treating cognitive issues due to Alzheimer's disease fails to meet the primary goal.

Lightwave Logic, Inc. (NASDAQ:LWLG) is no longer a reflexivity case to the extent that the general market isn't in a bearish spot, and they are moving to raise capital at fine prices. Revenues ...

Sage Therapeutics’ share price fell 11% to $6 in pre-market activity on Tuesday, after it announced disappointing top-line ...

Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results ...

Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the ...

Scientists have successfully demonstrated a low-coherence Brillouin optical correlation-domain reflectometry (BOCDR) system ...